WEBSITE BSE:500124 NSE : DR.REDDY'S 09 Jun, 12:37
Market Cap ₹77992 Cr.
Stock P/E 17.3
P/B 3.4
Current Price ₹4685
Book Value ₹ 1398.2
Face Value 5
52W High ₹4987
Dividend Yield 0.85%
52W Low ₹ 3996.1
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical corporation. The Company's segments consist of Global Generics, which is engaged in production and marketing prescription and over the counter finished pharmaceutical merchandise ready for consumption by patient, marketed under a brand name (branded formulations) or as usual finished dosages with healing equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and advertising and marketing active pharmaceutical elements and intermediates for finished pharmaceutical merchandise; Proprietary Products, which focuses on studies and development of differentiated formulations and Others, which includes the Company's absolutely-owned subsidiary, Aurigene Discovery Technologies Ltd, which is a discovery stage biotechnology organisation growing novel and treatments in the fields of oncology and inflammation.
Price goes above X
Price falls below X
₹ | |
#(Fig in Cr.) | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 4942 | 4768 | 4945 | 5787 | 5338 | 5475 | 5233 | 6332 | 6790 | 6315 |
Other Income | 71 | 83 | 108 | 206 | 56 | 122 | 854 | 41 | 59 | 139 |
Total Income | 5012 | 4851 | 5053 | 5992 | 5394 | 5597 | 6087 | 6373 | 6849 | 6454 |
Total Expenditure | 4403 | 3715 | 4211 | 4427 | 4123 | 5024 | 4292 | 4433 | 4851 | 4781 |
Operating Profit | 610 | 1136 | 842 | 1565 | 1272 | 573 | 1795 | 1940 | 1997 | 1672 |
Interest | 19 | 30 | 19 | 23 | 22 | 32 | 35 | 31 | 42 | 35 |
Depreciation | 311 | 309 | 284 | 294 | 294 | 293 | 302 | 309 | 324 | 316 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 280 | 797 | 539 | 1248 | 956 | 248 | 1459 | 1600 | 1632 | 1322 |
Provision for Tax | 267 | 258 | 175 | 277 | 265 | 162 | 279 | 499 | 394 | 369 |
Profit After Tax | 13 | 539 | 364 | 971 | 691 | 87 | 1180 | 1100 | 1238 | 953 |
Adjustments | 15 | 18 | 17 | 25 | 19 | 11 | 9 | 14 | 6 | 8 |
Profit After Adjustments | 28 | 557 | 380 | 996 | 709 | 97 | 1189 | 1114 | 1244 | 960 |
Adjusted Earnings Per Share | 1.7 | 33.5 | 22.9 | 59.8 | 42.6 | 5.8 | 71.5 | 67 | 74.7 | 57.6 |
#(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 9815 | 11896 | 13415 | 15023 | 15568 | 14196 | 14281 | 15448 | 17517 | 19048 | 21545 | 24670 |
Other Income | 132 | 154 | 196 | 275 | 295 | 172 | 155 | 338 | 621 | 291 | 485 | 1093 |
Total Income | 9947 | 12050 | 13611 | 15298 | 15863 | 14368 | 14436 | 15786 | 18138 | 19339 | 22030 | 25763 |
Total Expenditure | 7375 | 9176 | 10165 | 11530 | 11983 | 11724 | 11930 | 12270 | 15047 | 15178 | 17778 | 18357 |
Operating Profit | 2572 | 2874 | 3446 | 3769 | 3880 | 2644 | 2506 | 3516 | 3091 | 4161 | 4252 | 7404 |
Interest | 114 | 104 | 153 | 109 | 83 | 63 | 79 | 89 | 98 | 97 | 96 | 143 |
Depreciation | 518 | 550 | 648 | 760 | 939 | 1027 | 1077 | 1135 | 1163 | 1229 | 1165 | 1251 |
Exceptional Income / Expenses | -135 | -54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 1804 | 2165 | 2646 | 2900 | 2859 | 1554 | 1350 | 2336 | 1886 | 2884 | 3061 | 6013 |
Provision for Tax | 504 | 638 | 683 | 563 | 751 | 297 | 438 | 386 | -140 | 932 | 879 | 1541 |
Profit After Tax | 1301 | 1527 | 1963 | 2336 | 2108 | 1257 | 912 | 1950 | 2026 | 1952 | 2183 | 4471 |
Adjustments | 0 | 0 | 0 | 0 | 23 | 35 | 34 | 0 | 0 | 0 | 0 | 37 |
Profit After Adjustments | 1301 | 1527 | 1963 | 2336 | 2131 | 1292 | 947 | 1950 | 2026 | 1952 | 2183 | 4507 |
Adjusted Earnings Per Share | 76.7 | 89.9 | 115.3 | 137.1 | 124.9 | 77.9 | 57 | 117.5 | 121.9 | 117.3 | 131.2 | 270.8 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 13% | 12% | 9% | 8% |
Operating Profit CAGR | 2% | 7% | 10% | 5% |
PAT CAGR | 12% | 4% | 12% | 5% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | 8% | 4% | 18% | 8% |
ROE Average | 12% | 13% | 12% | 18% |
ROCE Average | 15% | 14% | 13% | 17% |
#(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|
Shareholder's Funds | 4989 | 6369 | 7865 | 9853 | 12570 | 12262 | 12572 | 14024 | 15599 | 17642 | 19212 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Borrowings | 1642 | 1266 | 2076 | 1432 | 1069 | 545 | 2509 | 2200 | 130 | 630 | 575 |
Other Non-Current Liabilities | -32 | 19 | 107 | 247 | -192 | -89 | 30 | -87 | -938 | -827 | -1083 |
Total Current Liabilities | 4591 | 5659 | 5790 | 6821 | 6347 | 8420 | 6894 | 5897 | 7214 | 8104 | 9766 |
Total Liabilities | 11190 | 13313 | 15838 | 18353 | 19794 | 21138 | 22004 | 22034 | 22005 | 25548 | 28470 |
Fixed Assets | 3412 | 4051 | 4641 | 5377 | 6563 | 6931 | 6968 | 7191 | 6850 | 8206 | 8122 |
Other Non-Current Assets | 780 | 736 | 871 | 1099 | 1437 | 4524 | 4537 | 3733 | 2556 | 2792 | 2560 |
Total Current Assets | 6999 | 8527 | 10326 | 11877 | 11794 | 9684 | 10498 | 11110 | 12599 | 14535 | 17788 |
Total Assets | 11190 | 13313 | 15838 | 18353 | 19794 | 21138 | 22004 | 22034 | 22005 | 25548 | 28470 |
#(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 573 | 736 | 520 | 862 | 540 | 492 | 378 | 254 | 223 | 196 | 1482 |
Cash Flow from Operating Activities | 1613 | 1378 | 1970 | 2524 | 3263 | 2144 | 1803 | 2870 | 2984 | 3570 | 2811 |
Cash Flow from Investing Activities | -1888 | -1446 | -1694 | -2265 | -2039 | -1840 | -1488 | -773 | -492 | -2266 | -2639 |
Cash Flow from Financing Activities | 389 | -157 | -24 | -433 | -1700 | -369 | -444 | -2133 | -2516 | -30 | -242 |
Net Cash Inflow / Outflow | 113 | -225 | 251 | -174 | -477 | -65 | -129 | -35 | -24 | 1275 | -70 |
Closing Cash & Cash Equivalent | 736 | 520 | 862 | 583 | 492 | 378 | 254 | 223 | 196 | 1482 | 1485 |
# | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|
Earnings Per Share (Rs) | 76.7 | 89.92 | 115.35 | 137.11 | 124.89 | 77.93 | 57.04 | 117.47 | 121.9 | 117.28 | 131.16 |
CEPS(Rs) | 107.25 | 122.32 | 153.39 | 181.71 | 178.58 | 137.74 | 119.86 | 185.83 | 191.88 | 191.13 | 201.18 |
DPS(Rs) | 13.75 | 15 | 18 | 20 | 20 | 20 | 20 | 20 | 25 | 25 | 30 |
Book NAV/Share(Rs) | 290.91 | 371.04 | 457.33 | 572.92 | 731.49 | 734.72 | 752.35 | 840.01 | 932.31 | 1052.59 | 1145.98 |
Core EBITDA Margin(%) | 24.75 | 22.72 | 24.08 | 23.13 | 23.03 | 17.41 | 16.46 | 20.57 | 14.1 | 20.32 | 17.49 |
EBIT Margin(%) | 19.47 | 18.96 | 20.74 | 19.92 | 18.89 | 11.39 | 10.01 | 15.7 | 11.33 | 15.65 | 14.65 |
Pre Tax Margin(%) | 18.31 | 18.09 | 19.61 | 19.19 | 18.36 | 10.94 | 9.46 | 15.12 | 10.76 | 15.14 | 14.21 |
PAT Margin (%) | 13.2 | 12.76 | 14.55 | 15.47 | 13.54 | 8.86 | 6.39 | 12.62 | 11.57 | 10.25 | 10.13 |
Cash Profit Margin (%) | 18.46 | 17.36 | 19.34 | 20.5 | 19.57 | 16.09 | 13.93 | 19.97 | 18.21 | 16.7 | 15.54 |
ROA(%) | 12.99 | 12.46 | 13.47 | 13.67 | 11.05 | 6.14 | 4.23 | 8.86 | 9.2 | 8.21 | 8.08 |
ROE(%) | 29.15 | 27.18 | 27.88 | 26.63 | 18.95 | 10.2 | 7.4 | 14.75 | 13.76 | 11.82 | 11.93 |
ROCE(%) | 26.24 | 24.83 | 25 | 22.7 | 19.55 | 9.77 | 8.21 | 13.66 | 11.12 | 15.49 | 14.59 |
Receivable days | 79.59 | 87.19 | 87.97 | 89.72 | 96.43 | 101.86 | 100.33 | 94.98 | 93.92 | 95.74 | 98.6 |
Inventory Days | 65.6 | 62.74 | 62.06 | 60.27 | 60.11 | 69.56 | 73.63 | 74.03 | 71.52 | 77.11 | 81.57 |
Payable days | 98.85 | 89.38 | 102.27 | 84.85 | 86.14 | 96.95 | 108.04 | 109.69 | 95.02 | 100.14 | 99.98 |
PER(x) | 22.93 | 19.64 | 22.2 | 25.43 | 24.3 | 33.78 | 36.51 | 23.62 | 25.57 | 38.5 | 32.83 |
Price/Book(x) | 6.05 | 4.76 | 5.6 | 6.09 | 4.15 | 3.58 | 2.77 | 3.3 | 3.34 | 4.29 | 3.76 |
Dividend Yield(%) | 0.78 | 0.85 | 0.7 | 0.57 | 0.66 | 0.76 | 0.96 | 0.72 | 0.8 | 0.55 | 0.7 |
EV/Net Sales(x) | 3.2 | 2.66 | 3.41 | 4.12 | 3.51 | 3.39 | 2.76 | 3.22 | 3.07 | 3.99 | 3.37 |
EV/Core EBITDA(x) | 12.23 | 11.02 | 13.28 | 16.42 | 14.08 | 18.22 | 15.71 | 14.13 | 17.41 | 18.29 | 17.08 |
Net Sales Growth(%) | 30.91 | 21.2 | 12.78 | 11.99 | 3.63 | -8.81 | 0.6 | 8.17 | 13.39 | 8.74 | 13.11 |
EBIT Growth(%) | 57.89 | 18.27 | 23.35 | 7.5 | -2.24 | -45.02 | -11.62 | 69.65 | -18.18 | 50.23 | 5.93 |
PAT Growth(%) | 30.23 | 17.36 | 28.58 | 19.01 | -9.79 | -40.35 | -27.43 | 113.72 | 3.9 | -3.67 | 11.83 |
EPS Growth(%) | 29.93 | 17.23 | 28.28 | 18.87 | -8.92 | -37.6 | -26.81 | 105.96 | 3.77 | -3.79 | 11.83 |
Debt/Equity(x) | 0.66 | 0.58 | 0.58 | 0.44 | 0.27 | 0.4 | 0.41 | 0.28 | 0.14 | 0.17 | 0.18 |
Current Ratio(x) | 1.52 | 1.51 | 1.78 | 1.74 | 1.86 | 1.15 | 1.52 | 1.88 | 1.75 | 1.79 | 1.82 |
Quick Ratio(x) | 1.1 | 1.12 | 1.37 | 1.36 | 1.46 | 0.81 | 1.1 | 1.31 | 1.26 | 1.23 | 1.3 |
Interest Cover(x) | 16.81 | 21.73 | 18.34 | 27.58 | 35.61 | 25.51 | 18.14 | 27.27 | 20.18 | 30.73 | 32.96 |
Total Debt/Mcap(x) | 0.11 | 0.12 | 0.1 | 0.07 | 0.06 | 0.11 | 0.15 | 0.08 | 0.04 | 0.04 | 0.05 |
# | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 26.73 | 26.74 | 26.73 | 26.72 | 26.72 | 26.72 | 26.71 | 26.71 | 26.7 | 26.7 |
FII | 29.13 | 29.03 | 29.04 | 27.76 | 27.42 | 25.16 | 25.87 | 26.26 | 27.29 | 27.25 |
DII | 14.73 | 14.9 | 15.74 | 21.4 | 22.29 | 24.78 | 25.19 | 24.7 | 23.38 | 23.05 |
Public | 16.29 | 17.13 | 16.4 | 12.07 | 12.04 | 12.12 | 11.87 | 12.26 | 12.1 | 11.7 |
Others | 13.12 | 12.21 | 12.09 | 12.05 | 11.53 | 11.23 | 10.37 | 10.08 | 10.53 | 11.3 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
FII | 4.85 | 4.83 | 4.83 | 4.62 | 4.56 | 4.19 | 4.31 | 4.37 | 4.54 | 4.54 |
DII | 2.45 | 2.48 | 2.62 | 3.56 | 3.71 | 4.12 | 4.19 | 4.11 | 3.89 | 3.84 |
Public | 2.71 | 2.85 | 2.73 | 2.01 | 2 | 2.02 | 1.98 | 2.04 | 2.01 | 1.95 |
Others | 2.18 | 2.03 | 2.01 | 2 | 1.92 | 1.87 | 1.73 | 1.68 | 1.75 | 1.88 |
Total | 16.63 | 16.63 | 16.64 | 16.64 | 16.64 | 16.64 | 16.64 | 16.65 | 16.65 | 16.65 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
See More Unlisted Share Articles
You May Also Know About